Clinuvel Pharmaceuticals CLVLF Stock
Clinuvel Pharmaceuticals Price Chart
Clinuvel Pharmaceuticals CLVLF Financial and Trading Overview
| Clinuvel Pharmaceuticals stock price | 5.89 USD |
| Previous Close | 5.89 USD |
| Open | 5.88 USD |
| Bid | 5.5 USD x 30000 |
| Ask | 6.37 USD x 30000 |
| Day's Range | 5.87 - 5.89 USD |
| 52 Week Range | 5.87 - 8.6 USD |
| Volume | 300 USD |
| Avg. Volume | 500 USD |
| Market Cap | 308.94M USD |
| Beta (5Y Monthly) | 0.562 |
| PE Ratio (TTM) | 12.270833 |
| EPS (TTM) | 0.48 USD |
| Forward Dividend & Yield | 0.04 (0.61%) |
| Ex-Dividend Date | September 3, 2026 |
| 1y Target Est | N/A |
CLVLF Valuation Measures
| Enterprise Value | 46.9M USD |
| Trailing P/E | 12.270833 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.2857249 |
| Price/Book (mrq) | 1.5185872 |
| Enterprise Value/Revenue | 0.499 |
| Enterprise Value/EBITDA | 1.141 |
Trading Information
Clinuvel Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.562 |
| 52-Week Change | -20.93% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 8.6 USD |
| 52 Week Low | 5.87 USD |
| 50-Day Moving Average | 6.44 USD |
| 200-Day Moving Average | 7.23 USD |
CLVLF Share Statistics
| Avg. Volume (3 month) | 500 USD |
| Avg. Daily Volume (10-Days) | 390 USD |
| Shares Outstanding | 50.43M |
| Float | 43.88M |
| Short Ratio | N/A |
| % Held by Insiders | 16.58% |
| % Held by Institutions | 13.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.05 |
| Trailing Annual Dividend Yield | 0.84% |
| 5 Year Average Dividend Yield | 28.99% |
| Payout Ratio | 0.0749 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | 36.07% |
| Operating Margin (ttm) | 47.32% |
| Gross Margin | 83.18% |
| EBITDA Margin | 43.72% |
Management Effectiveness
| Return on Assets (ttm) | 8.93% |
| Return on Equity (ttm) | 13.20% |
Income Statement
| Revenue (ttm) | 94.02M USD |
| Revenue Per Share (ttm) | 1.88 USD |
| Quarterly Revenue Growth (yoy) | -3.79% |
| Gross Profit (ttm) | 78.21M USD |
| EBITDA | 41.11M USD |
| Net Income Avi to Common (ttm) | 33.92M USD |
| Diluted EPS (ttm) | 0.48 |
| Quarterly Earnings Growth (yoy) | 6.20% |
Balance Sheet
| Total Cash (mrq) | 252.06M USD |
| Total Cash Per Share (mrq) | 5 USD |
| Total Debt (mrq) | 1.94M USD |
| Total Debt/Equity (mrq) | 0.71 USD |
| Current Ratio (mrq) | 14.812 |
| Book Value Per Share (mrq) | 3.878605 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 36.91M USD |
| Levered Free Cash Flow (ttm) | 25.39M USD |
Profile of Clinuvel Pharmaceuticals
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 535 Bourke Street |
| ZIP | 3000 |
| Phone | 61 3 9660 4900 |
| Website | https://www.clinuvel.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Q&A For Clinuvel Pharmaceuticals Stock
What is a current CLVLF stock price?
Clinuvel Pharmaceuticals CLVLF stock price today per share is 5.89 USD.
How to purchase Clinuvel Pharmaceuticals stock?
You can buy CLVLF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clinuvel Pharmaceuticals?
The stock symbol or ticker of Clinuvel Pharmaceuticals is CLVLF.
Which industry does the Clinuvel Pharmaceuticals company belong to?
The Clinuvel Pharmaceuticals industry is Biotechnology.
How many shares does Clinuvel Pharmaceuticals have in circulation?
The max supply of Clinuvel Pharmaceuticals shares is 52.45M.
What is Clinuvel Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Clinuvel Pharmaceuticals PE Ratio is 12.27083300 now.
What was Clinuvel Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Clinuvel Pharmaceuticals EPS is 0.48 USD over the trailing 12 months.
Which sector does the Clinuvel Pharmaceuticals company belong to?
The Clinuvel Pharmaceuticals sector is Healthcare.
